The application of modified cumulative illness rating scale-geriatric in the elder with the digestive tract cancer

Han Xinghua,Chen Zhendong
DOI: https://doi.org/10.3969/j.issn.1000-1492.2008.06.027
2008-01-01
Abstract:Objective To evaluate the prevalence of comorbidity and its impact on chemotherapy in elderly patients with the digestive tract cancer by the modified cumulative illness rating scale-geriatric(MCIRS-G). The clinical value of MCIRS-G used in elderly patients with gastrointestinal cancer was studied. Methods 80 patients with the digestive tract cancer treated with fluorouracil-based combination chemotherapy were divided into the elder group (≥65 years) and the control group (<65 years). MCIRS-G was used to note down comorbidities in detail. CTCAE Version 3.0 was used to evaluate the adverse effects from the beginning of the treatment to the end of the consequential four weeks. Adverse reactions caused by chemotherapy of the two groups were compared to study the differences according to the MCIRS-G scores,KPS scores and age stratification. Results There was a significant difference of the prevalence of comorbidity between the two groups(P<0.05). The score of MCIRS-G in the elderly group (16.19±2.25) was significantly higher than that of in the control group(14.67±1.08),P<0.001. With the increase in MCIRS-G score,there were marked hematotoxicity incidences of leukopenia(P=0.014),thrombocytopenia(P=0.010),anemia(P=0.031) in the elder group,incidence rates of other toxicities were very low. With the increases in MCIRS-G scores,the control group exhibited distinct change in the incidence of anemia(P=0.005). There was a positive correlation between MCIRS-G score and age,P=0.004,and there was no correlation between MCIRS-G score and KPS,P=0.375. Conclusion The MCIRS-G could be used to evaluate comorbidity of the elderly patients with digestive tract cancer effectively. There are no correlation between the score of MCIRS-G and KPS. MCIRS-G tends to be a more sensitive prognostic factor compared to KPS. Age should not be regarded as a restriction factor of chemotherapy while comorbidity should be.
What problem does this paper attempt to address?